Literature DB >> 15374844

A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.

Kwok C Chang1, Chi C Leung, Wing W Yew, Suzanne C Ho, Cheuk M Tam.   

Abstract

This nested case-control study aimed at evaluating treatment-related risk factors of relapse of tuberculosis under a service program of directly observed treatment. Out of 12,183 patients with pulmonary tuberculosis who completed treatment within 1 year, 113 relapsed within 30 months after commencement of therapy. The overall 30-month relapse rate was 0.9% (95% confidence interval [CI] 0.8-1.1%). On matching 113 cases with 226 control subjects in a conditional logistic model, thrice-weekly treatment increased the risk of relapse in comparison with daily treatment (odds ratio 3.92, 95% CI 1.78-8.63), whereas prolonging both intensive phase and overall treatment by 50% or more protected against relapse (odds ratio 0.24, 95% CI 0.08-0.70). When pretreatment culture was positive and cavitation was absent, the 30-month relapse rate for standard thrice-weekly regimen was 1.1% (95% CI 0.6-2.0%). The corresponding rates in the presence of cavitation were 7.8% (95% CI 4.0-14.6%) for standard thrice-weekly regimen; 3.3% (95% CI 1.9-5.5%) for standard daily regimen; 0.5% (95% CI 0.1-2.6%) for extended thrice-weekly regimen; and 0.4% (95% CI 0.1-0.9%) for extended daily regimen. Further studies are required to reduce the risk of relapse under program settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374844     DOI: 10.1164/rccm.200407-905OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  60 in total

1.  Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Authors:  Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

3.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

5.  Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis.

Authors:  Wen-Lin Su; Wann-Cherng Perng; Ching-Hui Huang; Cheng-Yu Yang; Chin-Pyng Wu; Jenn-Han Chen
Journal:  Clin Vaccine Immunol       Date:  2009-12-09

6.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

7.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

8.  Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment.

Authors:  Guang Xue He; Yan Guang Xie; Li Xia Wang; Martien W Borgdorff; Marieke J van der Werf; Ji Huan Fan; Xing Lu Yan; Fa Bin Li; Xue Zhi Zhang; Yan Lin Zhao; Susan van den Hof
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

9.  Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.

Authors:  Bo Young Lee; Sunyoung Kim; YoonKi Hong; Sang-Do Lee; Woo Sung Kim; Dong Soon Kim; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

10.  Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis.

Authors:  William J Burman; Erin E Bliven; Lauren Cowan; Lorna Bozeman; Payam Nahid; Lois Diem; Andrew Vernon
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.